Prostate Cancer | Current Treatment: Physician Insights | US | 2023
Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant prostate cancer (mCRPC) market and account for sizable market shares in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. They compete with other next-generation hormonal therapies like Erleada (Janssen) and Nubeqa (Bayer HealthCare), two brands initially approved for nonmetastatic castrate-resistant prostate cancer (nmCRPC). The PSMA-targeted radioligand therapy Pluvicto (Novartis), which the FDA approved in March 2022, is having an impact on the treatment of mCRPC. The PARP inhibitors Lynparza (AstraZeneca) and Rubraca (Clovis Oncology) offer other biomarker-driven options for mCRPC treatment, and Xofigo (Bayer HealthCare) and Jevtana (Sanofi) are other nonhormonal treatment options for mCRPC, particularly in later lines.
Questions Answered
- What are the drug-treatment rates across clinically and commercially relevant prostate cancer patient populations?
- What is the uptake of the PSMA radioligand therapy Pluvicto in mCRPC to date?
- What are the patient shares of key therapies in commercially relevant prostate cancer patient populations?
- What are the main drivers of and obstacles to the uptake of current therapies in select hormone-sensitive and castrate-resistant patient segments?
Product Description
Current Treatment: Physician Insights provides physician insights ontreatment dynamics, prescribing behavior, and drivers of brand useso that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 medical oncologists and urologists (50 of each specialty) in the United States fielded in May 2023.
Key drugs covered: Abiraterone, Xtandi, Erleada, Nubeqa, Orgovyx, Pluvicto, Provenge, Xofigo, Jevtana, Lynparza, Rubraca, others
